Bristol Myers Squibb (CELG-RI) Gross Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Gross Margin of 70.22% for Q1 2026, down 270.0% year-over-year from 41.31% in Q1 2025, and up 4.45% quarter-over-quarter from 67.23% in Q4 2025.
Bristol Myers Squibb (CELG-RI) Gross Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Gross Margin data on file, last reported at 70.22% in Q1 2026.
- Gross Margin for Q1 2026 came in at 70.22%, down 270.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 70.45% (down 1.0% YoY), and the FY2025 annual result was 71.08%, changed 0.0% from the prior year.
- Gross Margin climbed to 70.22% in Q1 2026 per CELG-RI's latest filing, from 67.23% in the prior quarter.
- Over five years, Gross Margin peaked at 79.02% in Q3 2022 and troughed at 61.01% in Q4 2024.
- A 5-year average of 73.92% and a median of 75.13% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin plunged 1507 bps in 2024, then surged 622 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 77.27% in 2022, then slipped by 2 bps to 76.08% in 2023, then retreated by 20 bps to 61.01% in 2024, then advanced by 10 bps to 67.23% in 2025, then grew by 4 bps to 70.22% in 2026.
- Business Quant data shows CELG-RI's Gross Margin at 70.22% in Q1 2026, 67.23% in Q4 2025, and 71.89% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 70.22% |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 70.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.22% |
| Dec 31, 2025 | 67.23% |
| Sep 30, 2025 | 71.89% |
| Jun 30, 2025 | 72.52% |
| Mar 31, 2025 | 72.92% |
| Dec 31, 2024 | 61.01% |
| Sep 30, 2024 | 75.13% |
| Jun 30, 2024 | 73.22% |
| Mar 31, 2024 | 75.29% |
| Dec 31, 2023 | 76.08% |
| Sep 30, 2023 | 77.15% |
| Jun 30, 2023 | 74.38% |
| Mar 31, 2023 | 77.37% |
| Dec 31, 2022 | 77.27% |
| Sep 30, 2022 | 79.02% |
| Jun 30, 2022 | 77.12% |
| Mar 31, 2022 | 78.79% |
| Dec 31, 2021 | 80.34% |
| Sep 30, 2021 | 80.29% |
| Jun 30, 2021 | 79.05% |